This biosimilar is manufactured in a cGMP compliant, ISO Quality Standard 9001:2015 facility. ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information. ichorbio: the best antibodies for in vivo research.
Human IgG1 λ
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only
DR5 is widely expressed in adult and fetal tissues, with notably high expression on tumor cells.
Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.
≥ 2.0 mg/ml
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 – 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
>99% by SDS-PAGE and HPLC
<0.5 EU/mg as determined by the LAL method
This biosimilar is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Agonist, ELISA, Functional Assays, Flow Cytometry, Immunofluorescence, Immunoprecipitation, Western Blotting
Each investigator should determine their own optimal working dilution for specific applications.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.